Wells Fargo analyst Tiago Fauth maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $26.00.
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Keros Therapeutics (KROS – Research Report). The ...
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results